TomoTherapy Reports Fourth Quarter Financial Results
Record Revenue, New Orders and Backlog
Madison, Wis. – Feb. 13, 2008 – TomoTherapy Incorporated (NASDAQ: TOMO) today released financial results for the fourth quarter ended December 31, 2007. TomoTherapy has developed, markets and sells the Hi·Art® treatment system, an advanced and versatile radiation therapy system for the treatment of a wide variety of cancers.
For the fourth quarter of 2007, the company reported revenue of $78.7 million, a 32% increase from $59.6 million in the fourth quarter of 2006. Net income was $4.8 million, or $0.09 per diluted share, compared to pro forma net income of $8.9 million, or $0.22 per diluted share, for the fourth quarter of 2006. The 2006 pro forma results included a $2.3 million tax benefit from the reversal of a portion of the company’s deferred tax valuation allowance and a $2.6 million benefit from the use of federal tax loss carryforwards; but do not include the reversal of the accretion of redeemable convertible preferred stock of $8.3 million. Including this reversal, the net income attributable to common shareholders was $17.2 million, or $1.90 per diluted share, for the three months ended December 31, 2006.
The value of new sales orders received during the 2007 fourth quarter totaled a record $92 million, a 25% increase over the fourth quarter of 2006, and up 26% sequentially from the 2007 third quarter.
“We showed outstanding sales performance in the fourth quarter,” said Fred Robertson, TomoTherapy’s CEO. “The record value of sales orders resulted in a healthy increase in our year-end backlog. We saw no impact from our competitors’ new product offerings.”
Among the company’s many accomplishments in 2007, TomoTherapy:
- received $292 million of new orders during the year, a 43% increase over 2006, and far above the market growth rate – estimated to be in the low teens;
- had another successful showing at ASTRO, its largest trade show, exceeding expectations for order intake in the fourth quarter and producing a strong pipeline for 2008;
- continued to penetrate single linac centers, further validating the versatility of the Hi·Art system;
- expanded its global footprint with the first Hi·Art installations in both China and India, and the addition of six distributors in the fourth quarter – who generated three orders before year end;
- enhanced the Hi·Art system with a new high performance couch and 3.1 software which, according to management, should result in improved reliability and up to a 30% improvement in patient throughput;
- continued to invest in future innovations, including $4.1 million related to the proton therapy project; and
- announced recently that it completed production of its 200th Hi·Art system.
As a result of these achievements, management estimates that the company’s market share now stands at 10% to 12% of the overall radiation therapy market, and 35% to 40% of the CT-based image-guided market – the fastest growing segment of the market.
“We believe that TomoTherapy’s performance validates our view that the Hi·Art system continues to provide patients with the highest quality treatments and health care providers with the greatest amount of clinical versatility,” added Robertson. “Our robust business gives us confidence that we will add to the market share gains that we attained in 2007.”
As of December 31, 2007, TomoTherapy had a record $248 million of revenue backlog, a 51% increase from the backlog at December 31, 2006. The backlog represents firm customer orders for systems and does not include any revenue from service contracts, which are a growing portion of the company’s business. TomoTherapy generally recognizes revenue upon customer acceptance. This only happens after the system is installed and fully operational. Acceptance usually occurs three to four weeks after delivery.
Full Year Results
For the 12 months ended December 31, 2007, TomoTherapy reported revenue of $232.8 million, a 49% increase from $156.1 million for 2006. Gross margins rose to 37.2% in 2007 from 34.2% in 2006. The margin improvement stemmed primarily from continued favorable pricing and the benefits of leveraging the fixed service and support infrastructure.
The 2007 net loss attributable to common shareholders was $226.9 million, or $6.35 per diluted share, compared to a net loss of $33.5 million, or $3.78 per diluted share, for 2006. These results include the accretion of redeemable convertible preferred stock of $237.6 million and $46.3 million for 2007 and 2006, respectively. The 2006 net loss also included a $2.1 million, or $0.24 per diluted share, after-tax charge for the cumulative effect of a change in accounting principle related to the valuation of preferred stock warrants.
Pro forma net income for 2007, which excludes the effects of the preferred stock accretion, was $10.7 million, or $0.21 per diluted share, compared to $12.8 million, or $0.32 per diluted share, for 2006. The 2006 pro forma results included a $7.2 million tax benefit from the reversal of a portion of the company’s deferred tax valuation allowance and a $2.9 million benefit from the use of federal tax loss carryforwards.
The charge for the accretion of redeemable convertible preferred stock represents a non-cash charge to the income statement because preferred stockholders had the option to put their shares back to the company at the shares’ current fair market value. The charge represents the change in value of those preferred shares for each reporting period until the completion of the initial public offering (IPO). The company is no longer subject to adjustments of this type because the put option was eliminated when those shares converted into common stock at the IPO date. At that time, the entire balance in temporary equity was added to additional paid in capital on the balance sheet.
According to Robertson, “Looking back on 2007, we are very pleased with our performance during TomoTherapy’s first year as a public company. In addition to the Hi·Art system enhancements, we expanded our domestic and international sales footprint, and made key infrastructure investments for sustained growth – allowing us to help more cancer patients in more locations going forward.”
Outlook
Robertson said, “We expect another strong year in 2008, building on our recent initiatives and success.” For fiscal 2008, management anticipates revenue of $290 million to $310 million and net income per share in the range of $0.34 to $0.39 per diluted share.
Most of the company’s revenue is recognized based on the customer’s acceptance of the Hi·Art system. Thus, quarter-to-quarter fluctuations in revenue should be expected. Management continues to believe that its business is more accurately gauged by growth in backlog and revenue on an annual basis.
Based on projected shipment dates for the Hi·Art system orders in backlog, the company currently anticipates 30% to 40% of its revenue will be generated in the first half of 2008. Due to the strong order flow in the second half of 2007 and the projected timing of customers’ construction projects, more of the units in backlog are scheduled to be delivered in the second half of 2008. In addition, more customers were ready to take shipments in the fourth quarter of 2007, which created a somewhat stronger quarter at the expense of the 2008 first quarter.
Added Robertson, “Based on the rapid global adoption of image-guided systems, we believe that TomoTherapy’s technology leadership position will allow us to continue to increase our market share in 2008 by growing new orders at a rate greater than the overall annual market growth rate.”
Investor Conference Call
TomoTherapy will conduct a conference call on its fourth quarter 2007 results at 5:00 p.m. EST today (4:00 p.m. CST). To hear a live Webcast or replay of the call, visit the Investor Relations page, where it will be archived for two weeks. To access the call via telephone, dial 1-866-510-0712 from inside the United States or 1-617-597-5380 from outside the United States, and enter passcode 95806532. The replay can be accessed by dialing 1-888-286-8010 from inside the United States or 1-617-801-6888 from outside the United States and entering passcode 27979452. The telephone replay will be available through 11:59 a.m. CST on Friday, February 15, 2008.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007. Its stock is traded on the NASDAQ Global Market under the symbol TOMO.
Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning market acceptance of our technology; growth drivers; the company’s orders, revenue, backlog or earnings growth; future financial results and any statements using the terms “should,” “believe,” “outlook,” “expect” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results to differ materially from those anticipated. Such risks and uncertainties include: demand for the company’s products; impact of sales cycles and competitive products and pricing; the effect of economic conditions and currency exchange rates; the company’s ability to develop and commercialize new products; its reliance on sole or limited-source suppliers; its ability to increase gross margins; the company’s ability to meet U.S. Food and Drug Administration (FDA) and other regulatory agency product clearance and compliance requirements; the possibility that material product liability claims could harm future revenue or require the company to pay uninsured claims; the company’s ability to protect intellectual property; the impact of managed care initiatives, other health care reforms and/or third-party reimbursement levels for cancer care; potential loss of key distributors or key personnel; risk of interruptions to its operations due to terrorism, disease or other events beyond the company’s control; and the other risks listed from time to time in the company’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
TomoTherapy Incorporated
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
2007 2006 2007 2006
------------------- ---------------------
(Unaudited) (Unaudited)
Revenue $78,711 $59,598 $232,810 $156,102
Cost of revenue 50,443 36,802 146,137 102,653
------------------- ---------------------
Gross profit 28,268 22,796 86,673 53,449
Operating expenses:
Research & development 9,833 7,369 34,304 21,397
Selling, general &
administrative 13,463 8,241 42,307 23,119
------------------- ---------------------
Total operating expenses 23,296 15,610 76,611 44,516
------------------- ---------------------
Income from operations 4,972 7,186 10,062 8,933
Other income (expense), net 2,441 (52) 6,388 (1,202)
------------------- ---------------------
Income before income tax and
cumulative effect of change
in accounting principle 7,413 7,134 16,450 7,731
Income tax expense (benefit) 2,567 (1,736) 5,788 (7,184)
------------------- ---------------------
Income before cumulative
effect of change in
accounting principle 4,846 8,870 10,662 14,915
Cumulative effect of change
in accounting principle -- -- -- (2,140)
------------------- ---------------------
Net income 4,846 8,870 10,662 12,775
Accretion of redeemable
convertible preferred stock -- 8,310 (237,582) (46,253)
------------------- ---------------------
Net income (loss)
attributable to common
shareholders $4,846 $17,180 $(226,920) $(33,478)
=================== =====================
Net income (loss) per share
attributable to common
shareholders
Basic $0.10 $1.90 $(6.35) $(3.78)
=================== =====================
Diluted $0.09 $1.90 $(6.35) $(3.78)
=================== =====================
Weighted average common
shares outstanding used in
computing net income (loss)
per share attributable to
common shareholders
Basic 49,547 9,054 35,731 8,856
=================== =====================
Diluted 54,066 9,054 35,731 8,856
=================== =====================
Pro forma net income per
share
Basic $0.10 $0.25 $0.24 $0.36
=================== =====================
Diluted $0.09 $0.22 $0.21 $0.32
=================== =====================
Weighted average common
shares outstanding used in
computing pro forma net
income per share
Basic 49,547 35,564 45,028 35,366
=================== =====================
Diluted 54,066 40,593 49,919 40,130
=================== =====================
TomoTherapy Incorporated
Condensed Consolidated Balance Sheets
(In thousands)
Dec. 31, Dec. 31,
2007 2006
----------- -----------
(Unaudited)
Assets
-----------------------------------------------
Current assets:
Cash & investments $191,780 $20,137
Accounts receivable 44,596 19,050
Inventories 53,171 40,026
Deferred tax assets 3,433 5,982
Other current assets 1,622 1,014
----------- -----------
Total current assets 294,602 86,209
Property & equipment, net 19,894 15,469
Other long term assets, net 6,642 5,821
Deferred tax assets 6,027 1,815
----------- -----------
Total $327,165 $109,314
=========== ===========
Liabilities & Stockholders' Equity
-----------------------------------------------
Current liabilities:
Accounts payable $17,655 $13,960
Accrued expenses 29,672 17,974
Customer deposits 20,309 23,103
Deferred revenue 15,517 20,204
Convertible preferred stock warrant liability -- 3,522
----------- -----------
Total current liabilities 83,153 78,763
Other non-current liabilities 5,318 2,005
Temporary equity -- 212,663
Total stockholders' equity (deficit) 238,694 (184,117)
----------- -----------
Total $327,165 $109,314
=========== ===========
TomoTherapy Incorporated
Condensed Consolidated Statements of Cash Flows
(In thousands)
Twelve Months Ended
December 31,
-----------------------
2007 2006
----------- -----------
(Unaudited)
Operating Activities
Net income $10,662 $12,775
Adjustments to reconcile income to net
operating cash:
Depreciation and amortization 6,503 3,053
Stock-based compensation 3,318 232
Convertible preferred stock warrants 106 3,078
Deferred income tax provision 3,544 (7,797)
Excess tax benefit from share-based
compensation (3,800) --
Other non-cash items 771 (83)
Accounts receivable (25,546) (4,815)
Inventories (13,145) (11,743)
Other current assets (608) (176)
Accounts payable 3,695 6,618
Accrued expenses 12,888 8,734
Deferred revenue & customer deposits (7,481) (5,974)
----------- -----------
Net cash used in operating activities (9,093) 3,902
Net cash used in investing activities (11,770) (16,023)
Net cash provided by financing activities 193,029 1,862
Effect of exchange rate changes on cash (523) --
----------- -----------
Increase in cash 171,643 (10,259)
Cash and cash equivalents at beginning of
period 20,137 30,396
----------- -----------
Cash and cash equivalents at end of period $191,780 $20,137
=========== ===========
CONTACT: TomoTherapy Incorporated
Stephen C. Hathaway, CFO, 608-824-2800
13 Feb 2008
